GRG's Center For Experiential Learning

Metastatic melanoma was once a near-certain death sentence, but PD-1/PD-L1 inhibitors have rewritten the story. From survival rates once measured in months to long-term remission and renewed hope, immune checkpoint therapies like nivolumab and pembrolizumab are transforming cancer care and reshaping the future of oncology.

Melanoma, the deadliest form of skin cancer, has long been a formidable challenge in oncology. While early-stage melanoma can often be...